Issue 19, 2014

Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease

Abstract

Alzheimer's disease is the most common form of age-related neurodegenerative dementia. The disease is characterised by the presence of plaques in the cerebral cortex. The major constituent of these plaques is aggregated amyloid-β peptide. This review focuses on the molecular aspects of metal complexes designed to bind to amyloid-β. The development of radioactive metal-based complexes of copper and technetium designed as diagnostic imaging agents to detect amyloid burden in the brain is discussed. Separate sections of the review discuss the use of luminescent metal complexes to act as non-conventional probes of amyloid formation and recent research into the use of metal complexes as inhibitors of amyloid formation and toxicity.

Graphical abstract: Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease

Article information

Article type
Review Article
Submitted
15 Jan 2014
First published
27 Mar 2014
This article is Open Access
Creative Commons BY license

Chem. Soc. Rev., 2014,43, 6701-6715

Author version available

Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease

D. J. Hayne, S. Lim and P. S. Donnelly, Chem. Soc. Rev., 2014, 43, 6701 DOI: 10.1039/C4CS00026A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements